Avacopan Phase 1 Study Results 9/11/2024
Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vascultis. Shichang Milao, Pablo Suso, John A. Furst, Matthew G Hudson, Ashit Trivedi First Published 11 July 2024 | https://doi.org/10.1002/cpdd.1444 This article provides details showing the effect of hepatic impairment on the pharmacokinetics of avacopan capsules for oral use. [...]